Physician profile
Henda Bouali
NPI 1053495465
$6,855.31
in general payments reported to CMS, 2019-2025
11 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,918 · 2020: $17.40 · 2021: $266 · 2022: $2,526 · 2023: $456 · 2024: $371 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,944.75 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $2,133.43 | 2019-2023 | Tremfya |
| Abbvie INC. | $931.53 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $439.85 | 2019-2025 | Tavneos, Evenity, Prolia |
| Janssen Scientific Affairs, LLC | $198.83 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $106.60 | 2021-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $29.44 | 2024 | Purified Cortrophin Gel |
| Radius Health, INC. | $24.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.40 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $16.67 | 2024 | Zilretta |
| Lilly USA, LLC | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henda Bouali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.